Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

It is a randomised, double-blinded clinical trial in which consenting participants who meet the inclusion criteria would be randomised into 2 groups. Subjects will be given either preserved or preservative free latanoprost for a period of 12 weeks. The efficacy and tolerability of both drugs would be assessed every 4 weeks, amongst these patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Uzoma Chinyei Joan
• Treatments: Latanoprost; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Recently diagnosed, consenting high tension, primary open angle glaucoma or ocular hypertensive patients.

• Forty years and above.

• Intraocular pressure of 21- 30mmHg (millimetres of mercury)

• Willingness to participate in the study.

Exclusion Criteria:

• Patients under 40 years of age.

• Diabetic patients

• Patients on other anti- glaucoma medications.

• Patients on topical immunosuppressive medication.

• Patients on anti-depressants.

• Patients who have had any form of ocular surgery or intervention such as cryotherapy.

• Patients using contact lens.

• Patients on any form of topical medication in the last 1 month.

• Patients diagnosed or suspected to have Sjogren syndrome.

• Patients being managed for Steven-Johnson's syndrome, ocular cicatricial pemphigoid.

• Pregnant patients.

• Previous glaucoma surgery and any refractive surgery <12 month prior to enrolment.

• Only eye patients.